XPXuwang Pan

Xuwang Pan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xuwang Pan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Yidan Shao

    Pharmacy Department, Affiliated Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China

    2 shared publications
  • Yunjiang Li

    Radiology Department, Affiliated Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China

    2 shared publications
  • Zuhua Chen

    Radiology Department, Affiliated Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China

    2 shared publications
  • Fanzhu Li

    School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China

    1 shared publication
  • Jianfeng Bao

    Hepatology Department, Affiliated Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China

    1 shared publication
  • Jianhua Yu

    Hepatology Department, Affiliated Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Sequential-Delivery Gel Microspheres Integrating HAase-Mediated ECM Remodeling and GA-Active Targeting for Deep Tumor Penetration in TACE-Treated HCC

    by Xuwang Pan, Yunjiang Li, Yidan Shao, Jinsong Huang, Jianhua Yu, Zuhua Chen, Jianfeng Bao, Fanzhu Li, Rangxiao Zhuang

    Objective: Transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) is limited by inadequate intratumoral drug penetration. We developed a sequential-delivery composite gel microsphere system integrating hyaluronidase (HAase)-mediated microenvironment remodeling, glycyrrhetinic acid (GA)-mediated active targeting, and pH-responsive drug release as a potential strategy to address this barrier. Methods: Bufalin (BUF)-loaded GA-PEG-HYD-PLGA nanoparticles and HAase were co-encapsulated within carboxymethyl chitosan/sodium alginate gel microspheres containing BaSO4 for radiopacity (HAase/BUF NPs-GM). The system was characterized for particle size, drug loading, pH-responsive release, and hemocompatibility. Antitumor efficacy, deep tumor penetration, and mechanisms were evaluated in Huh-7 cells and a rabbit VX2 orthotopic liver tumor model via TACE-guided arterial delivery. Results: HAase/BUF NPs-GM exhibited a favorable size (270 ± 61.89 μm), pH-dependent BUF release, and good biocompatibility, with an IC50 of 55.07 nM against Huh-7 cells. The system reduced hyaluronic acid content across all tumor regions, consistent with enhanced penetration of the therapeutic payload into the tumor core. Compared with controls, HAase/BUF NPs-GM combined with TACE suppressed tumor growth and angiogenesis, induced apoptosis, inhibited proliferation, and was associated with increased intratumoral CD3⁺ T cell infiltration and reduced expression of EMT-related markers. Mechanistically, the system induced ROS overproduction, mitochondrial membrane potential decrease, and G2/M cell cycle arrest. Conclusion: This strategy, which combines microenvironment remodeling, active targeting, and responsive release, provides a promising preclinical proof-of-concept for addressing the penetration limitations of conventional TACE. Further translational investigation, including validation in orthotopic or patient-derived xenograft models and long-term toxicity assessment, is warranted.

  • Open Access

    Extensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC

    by Xing Liu, Yidan Shao, Yunjiang Li, Zuhua Chen, Tingting Shi, Qiao Tong, Xi Zou, Liping Ju, Jinming Pan, Rangxiao Zhuang, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world, mainly because of its powerful pro-connective tissue proliferation matrix and immunosuppressive tumor microenvironment (TME), which promote tumor progression and metastasis. In addition, the extracellular matrix leads to vascular collapse, increased interstitial fluid pressure, and obstruction of lymphatic return, thereby hindering effective drug delivery, deep penetration, and immune cell infiltration. Therefore, reshaping the TME to enhance tumor perfusion, increase deep drug penetration, and reverse immune suppression has become a key therapeutic strategy. Traditional therapies for PDAC, including surgery, radiation, and chemotherapy, face significant limitations. Surgery is challenging due to tumor location and growth, while chemotherapy and radiation are hindered by the dense extracellular matrix and immunosuppressive TME. In recent years, the advancement of nanotechnology has provided new opportunities to improve drug efficacy. Nanoscale drug delivery systems (NDDSs) provide several advantages, including improved drug stability in vivo, enhanced tumor penetration, and reduced systemic toxicity. However, the clinical translation of nanotechnology in PDAC therapy faces several challenges. These include the need for precise targeting and control over drug release, potential immune responses to the nanocarriers, and the scalability and cost-effectiveness of production. This article provides an overview of the latest nanobased methods for achieving better therapeutic outcomes and overcoming drug resistance. We pay special attention to TME-targeted therapy in the context of PDAC, discuss the advantages and limitations of current strategies, and emphasize promising new developments. By emphasizing the enormous potential of NDDSs in improving the treatment outcomes of patients with PDAC, while critically discussing the limitations of traditional therapies and the challenges faced by nanotechnology in achieving clinical breakthroughs, our review paves the way for future research in this rapidly developing field.